tapebrief
VRTX · Q3 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VRTX · Q4 2025 Earnings

Vertex Pharmaceuticals

Reported February 12, 2026

30-second summary

Vertex closed FY2025 at the high end of its revenue guide ($12.0B, +9% YoY) on Q4 FY2025 revenue of $3.19B (+10% YoY) and non-GAAP EPS of $5.03, then set FY2026 revenue guidance at $12.95–13.1B (8–9% growth) with an explicit $500M+ floor for non-CF products — roughly 3x the ~$175M non-CF contribution (CASGEVY $115.8M + JOURNAVX $59.6M) in FY2025. The most important quiet disclosure: Q1 FY2026 is guided at ~7% YoY growth, below the FY midpoint, meaning Vertex is telegraphing back-half acceleration driven by Journavx scaling (550,000+ FY Rx, 200M+ covered lives by January 2026), Alyftrek conversion, and Casgevy infusion ramp from 64 FY infusions.

Headline numbers

EPS

Q4 FY2025

$5.03

Revenue

Q4 FY2025

$3.19B

+10.0% YoY

Gross margin

Q4 FY2025

85.4%

Operating margin

Q4 FY2025

37.8%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$3.19B+10.0%$3.08B+3.6%
EPS$5.03—$4.80+4.8%
Gross margin85.4%—86.5%-110bps
Operating margin37.8%—38.6%-80bps

Guidance

Vertex raised FY2026 revenue guidance to $12.95-13.1B (8-9% growth), up from prior FY2025 $11.9-12.0B; Q1 2026 guided ~7% YoY growth; new non-CF revenue floor of $500M+ and narrowed operating expense range signal confidence in diversified growth and operational efficiency.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueFY2025$11.9 to $12.0 billion$12.0 billionat the high end of prior guideBeat

New guidance

MetricPeriodGuideYoY
RevenueFY2026$12.95 to $13.1 billion8% to 9% YoY
Revenue growthQ1 FY2026approximately 7% year-over-yearapproximately 7% YoY
Combined non-GAAP R&D, AIPR&D and SG&A expensesFY2026$5.65 to $5.75 billion—
Non-GAAP effective tax rateFY202619.5% to 20.5%—
Non-CF product revenueFY2026$500 million or more—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
TRIKAFTA/KAFTRIO$2.573B-5.4%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
United States$2.06B+12.0%
Outside United States$1.13B+5.0%
CASGEVY Patients Infused (Q4 2025)30—
CASGEVY Patients Infused (Full Year 2025)64—
CASGEVY First Cell Collections (Full Year 2025)147—
JOURNAVX Prescriptions Written (Through Year-end 2025)550000+—
JOURNAVX U.S. Covered Lives (January 2026)200 million+—
Operating Margin (Non-GAAP)42.9%—
Cash and Marketable Securities$12.3 billion—
CF Therapy Coverage (% of population)95% of core markets—

Management tone

Q1 FY2025 multi-franchise execution → Q2 FY2025 strategic discipline (killing VX993 mono, narrowing PNP to DPN) → Q3 FY2025 capacity expansion (initiating second renal indication, building commercial team) → Q4 FY2025 franchise reframing (renal "will rival CF scale", POVI as multi-disease platform)

Renal has been re-rated from "fourth franchise" to a future CF-equivalent. Three quarters ago renal was a single Phase 3 program (POVI in IgAN). Two quarters ago Vertex initiated the membranous nephropathy pivotal before the IgAN data read. This quarter management explicitly stated "the renal franchise will ultimately rival the scale of our CF business, and we're seeking to bring the best elements of our success in CF to these kidney disease areas." Companies don't compare a non-revenue franchise to a $11B+ business unless conviction is at conviction-call level. The signal: Vertex now believes the renal opportunity is multi-indication, multi-decade, and large enough to absorb the post-2030 CF maturation curve.

POVI has graduated from single-indication asset to multi-disease platform. A quarter ago POVI was an IgAN drug with a quiet second indication being added. This quarter management used the phrase "we believe POVI's mechanism of action and specifically engineered protein format provide best-in-class potential in myasthenia" — claiming best-in-class status in a brand new therapeutic area (neurology) before Phase 2 readout. The mechanism (BAF-APRIL) is now being pitched as a generalized auto-immune platform spanning IGAN, membranous, myasthenia, and ADPKD. This is the most aggressive cross-indication framing Vertex has used outside CF.

Journavx has gone from launch pain product to franchise with line-of-sight, with revenue building under PSP-suppressed GTN. Two quarters ago Journavx was "early days of another multi-billion dollar franchise" at 300,000 YTD Rx and $20M Q3 FY2025 revenue. This quarter Vertex announced plans to "more than triple the number of Journavx prescriptions compared to the approximately 550,000 written in 2025" and double the field force in Q2 FY2026. Q4 FY2025 prescriptions matched the cumulative total of the prior three quarters, while reported revenue grew sequentially to $26.7M — management explicitly tied the muted revenue conversion to the patient support program and committed to a PSP sunset in late FY2026/early FY2027 that should normalize GTN.

Casgevy went from sequential disappointment to a high-confidence revenue pillar. Q3 FY2025 infusions decelerated to ~10 from 16 in Q2 FY2025 and was a watch item flagged for negative resolution. Q4 FY2025 delivered 30 infusions in a single quarter (FY total 64, 147 cell collections setting up FY2026) — a 3x sequential acceleration that validates management's claim of "great line of sight to the year" on the $500M+ non-CF revenue floor. The honest caveat from management: "continued quarter-to-quarter variability in CASGEVY infusions in 2026" — they're explicitly resetting expectations away from linear ramp.

Tone on commercial spend has shifted from "we're spending to scale" to "the spend is producing returns." The 200M+ covered lives, 90% Casgevy access, 21-state Medicaid coverage for Journavx, and 74 payer engagements for POVI are quantified payer metrics that didn't appear in prior calls. This is the first quarter Vertex has tied payer infrastructure to specific patient population numbers across all four franchises simultaneously.

Recurring themes management leaned on this quarter:

Renal franchise emergence as fourth major vertical rivaling CF scaleMulti-indication potential for POVI across immunology (IGAN, membranous, myasthenia, ADPKD)Diversified revenue base with non-CF products reaching $500M+ (vs. $176M in 2025)Pediatric expansion in CF (Oliftrec 2-5 year data, younger age group trials)Commercial execution and payer access securing (90% access for Casgevi, 21 states Medicaid for Genavix, 74 payer engagements for POVI)Serial innovation commitment across entire portfolio (next-gen 3.0 CFTR modulators, VX522 for non-protein producers)

Risks management surfaced:

Hypogammaglobulinemia risk from BAF-APRIL inhibition in POVI (mitigated by Ruby 3 safety data showing no SAEs or infections)Anti-drug antibodies (ADAs) and neutralizing antibodies (NABs) for chronic POVI dosingBaseline GFR variability between Phase 2 and Phase 3 POVI studies potentially impacting effect sizePlacebo response variability in POVI Phase 3 Rainier study (0-5% estimated range based on physician input)Genavix gross-to-net pressure from patient support programs persisting into 2026 (expected to normalize in late 2026/early 2027)Quarterly variability in Casgevi infusions based on patient journey duration (expected to smooth by 2027)

Answers to last quarter's watch list

POVI BLA submission confirmation — The press release commits to "complete the BLA submission in the first half of this year if the Phase III interim analysis results are supportive" — a softer commitment than the Q3 FY2025 framing of "before the end of this year." The submission has slipped from a YE2025 commitment to a 1H FY2026 commitment contingent on interim data. Status: Resolved negatively
Journavx net revenue per Rx — Q4 FY2025 revenue of $26.7M against very strong Q4 prescription volume (equal to the prior three quarters combined) confirms that GTN remains heavily suppressed by the patient support program. Net per Rx remains well below the $100+ unlock threshold flagged last quarter. Management committed to sunsetting PSP in late FY2026/early FY2027 to normalize economics, and the $500M+ FY2026 non-CF guide implicitly underwrites material Journavx GTN improvement in H2 FY2026. Status: Continue monitoring
Combined CF franchise growth rate — Combined Trikafta/Kaftrio ($2.57B) + Alyftrek ($380M) = $2.95B in Q4 FY2025, roughly +7% YoY combined. Holding mid-single-digits, but Trikafta turned negative YoY (−5.4%) for the first time. Pace is acceptable; the underlying mix shift is more abrupt than previously framed. Status: Continue monitoring
Casgevy quarterly infusion pace — 30 infusions in Q4 FY2025 vs. 10 in Q3 FY2025 — a clean reacceleration past the >15 threshold and the strongest single quarter to date. FY total of 64 infused on 147 cell collections sets up a fuller FY2026 ramp. The FY2026 framing of "quarter-to-quarter variability" is a deliberate reset. Status: Resolved positively
FY2026 opex guide directionality — Combined non-GAAP R&D + AIPR&D + SG&A guided to $5.65–5.75B vs. $5.0–5.1B prior FY2025 guide — a directly comparable ~12% step-up. Management is funding a field-force doubling for Journavx and accelerated POVI work, confirming the pivot from launch-spike to permanent multi-franchise cost structure. Status: Resolved positively (directionally — spend is permanent)
Povetacicept second-indication trial enrollment pace — No enrollment cadence disclosed in the print. Management confirmed continued commitment to membranous nephropathy and expanded POVI into myasthenia gravis (a third indication), suggesting internal conviction remains high, but no enrollment data to benchmark against the IgAN 600-patient/15-month pace. Status: Not resolved

What to watch into next quarter

Q1 FY2026 actual revenue vs. ~7% YoY guide — the gap between Q1 FY2026 ~7% and FY 8–9% implies back-half acceleration; watch whether Q1 FY2026 prints in line, hot, or cold, since a Q1 miss makes the FY guide structurally back-half-dependent and raises FY2026 risk

Journavx net revenue per Rx normalization — the FY2026 $500M+ non-CF floor implicitly requires Journavx GTN to improve materially as the PSP sunsets; watch Q1 FY2026 reported Journavx revenue and whether management discloses a more concrete PSP wind-down timeline

Casgevy quarterly infusion pace holding above 25 — Q4 FY2025 delivered 30; with 147 FY cell collections in the funnel, Q1 FY2026 should sustain ≥25 infusions to validate management's "continued growth" framing — anything below 20 reignites the variability concern

POVI Phase 3 IgAN interim analysis readout — the BLA submission is now explicitly contingent on supportive interim data; watch the timing and quality of the interim analysis disclosure, since a delay or equivocal readout pushes the accelerated approval timeline into FY2027

Trikafta/Kaftrio YoY trajectory — first negative YoY quarter (−5.4%) in Q4 FY2025; watch whether the rate of decline stabilizes or accelerates as Alyftrek conversion continues, since the combined CF franchise growth depends on Alyftrek out-ramping Trikafta erosion

POVI myasthenia gravis Phase 2 initiation timing — management's "best-in-class" claim in neurology is the most aggressive forward language in the call; watch for explicit trial start dates and Phase 2 design disclosures, since these will determine when neurology becomes a real (vs. aspirational) franchise

Sources

  1. Vertex Pharmaceuticals Q4 FY2025 press release (SEC EDGAR Ex-99.1): https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm
  2. Vertex Pharmaceuticals Q3 FY2025 press release and Tapebrief Q3 brief (prior quarter context)
  3. Vertex Pharmaceuticals Q2 FY2025 press release and Tapebrief Q2 brief (prior quarter context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.